Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2017 | Pages:
63 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Prader-Willi Syndrome (PWS) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Prader-Willi Syndrome (PWS) - Pipeline Review, H2 2017, provides an overview of the Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline landscape. Prader-Willi Syndrome (PWS) is a rare genetic disorder present at birth that results in a number of physical, mental and behavioral problems. Symptoms include poor muscle tone, low levels of sex hormones and a constant feeling of hunger. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Prader-Willi Syndrome (PWS) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Prader-Willi Syndrome (PWS) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Prader-Willi Syndrome (PWS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 1, 4 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively. Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Prader-Willi Syndrome (PWS) (Genetic Disorders). - The pipeline guide reviews pipeline therapeutics for Prader-Willi Syndrome (PWS) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Prader-Willi Syndrome (PWS) (Genetic Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Prader-Willi Syndrome (PWS) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Prader-Willi Syndrome (PWS) (Genetic Disorders) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Prader-Willi Syndrome (PWS) (Genetic Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Prader-Willi Syndrome (PWS) - Overview Prader-Willi Syndrome (PWS) - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Prader-Willi Syndrome (PWS) - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Prader-Willi Syndrome (PWS) - Companies Involved in Therapeutics Development Alize Pharma SAS Capnia Inc Ferring International Center SA Insys Therapeutics Inc LG Chem, Ltd. Saniona AB Prader-Willi Syndrome (PWS) - Drug Profiles (metoprolol + tesofensine) - Drug Profile Product Description Mechanism Of Action R&D Progress AZP-531 - Drug Profile Product Description Mechanism Of Action R&D Progress cannabidiol - Drug Profile Product Description Mechanism Of Action R&D Progress carbetocin - Drug Profile Product Description Mechanism Of Action R&D Progress D-Tagatose - Drug Profile Product Description Mechanism Of Action R&D Progress diazoxide - Drug Profile Product Description Mechanism Of Action R&D Progress diazoxide choline CR - Drug Profile Product Description Mechanism Of Action R&D Progress HM-04 - Drug Profile Product Description Mechanism Of Action R&D Progress KAL-671 - Drug Profile Product Description Mechanism Of Action R&D Progress oxytocin - Drug Profile Product Description Mechanism Of Action R&D Progress Peptides for Severe Obesity, Prader-Willi Syndrome, Diabetes, and Fatty Liver Disease - Drug Profile Product Description Mechanism Of Action R&D Progress setmelanotide - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Activate snRNP-N for Prader-Willi Syndrome - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Glycogen Synthase for Prader-Willi Syndrome and Glycogen Storage Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress somatropin - Drug Profile Product Description Mechanism Of Action R&D Progress Prader-Willi Syndrome (PWS) - Dormant Projects Prader-Willi Syndrome (PWS) - Discontinued Products Prader-Willi Syndrome (PWS) - Product Development Milestones Featured News & Press Releases Apr 03, 2017: Saniona initiates Phase 2a study for Tesomet in Prader-Willi syndrome Mar 20, 2017: Saniona expects to initiate the planed Phase 2a study for Tesomet in Prader-Willi syndrome in Q2 2017 Nov 07, 2016: Saniona Plans To Initiate Phase 2A Study In Prader-Willi In 2017 Jul 20, 2016: Kalytera Therapeutics Presents New Data Demonstrating KAL671 Ability to Prevent Bone Loss in a Prader-Willi Syndrome Animal Model Jul 18, 2016: Alize Pharma to present results from AZP-531 Phase II trial in Prader-Willi syndrome at two upcoming scientific conferences Jul 05, 2016: Kalytera Therapeutics to Present New Data That Supports the Continued Investigation of KAL671 for the Treatment of Osteoporosis in Prader-Willi Syndrome at the IPWSO Conference Apr 26, 2016: Alize Pharma reports positive results from its Phase II clinical trial of AZP-531 in Prader-Willi Syndrome Jan 07, 2016: Rhythm Receives Orphan Drug Designation for Setmelanotide for the Treatment of Prader-Willi Syndrome Sep 24, 2015: FDA Office of Orphan Products Development Awards Rhythm $1 Million Grant to Support Phase 2 Study of Setmelanotide in Prader-Willi Syndrome Jun 04, 2015: Rhythm Initiates Two Phase 2 Clinical Trials of Setmelanotide in Rare Genetic Disorders of Obesity Caused by MC4 Pathway Deficiencies Mar 02, 2015: Alize Pharma launches Phase II clinical trial of AZP-531 in Prader-Willi syndrome Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Prader-Willi Syndrome (PWS), H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Prader-Willi Syndrome (PWS) - Pipeline by Alize Pharma SAS, H2 2017 Prader-Willi Syndrome (PWS) - Pipeline by Capnia Inc, H2 2017 Prader-Willi Syndrome (PWS) - Pipeline by Ferring International Center SA, H2 2017 Prader-Willi Syndrome (PWS) - Pipeline by Insys Therapeutics Inc, H2 2017 Prader-Willi Syndrome (PWS) - Pipeline by LG Chem, Ltd., H2 2017 Prader-Willi Syndrome (PWS) - Pipeline by Saniona AB, H2 2017 Prader-Willi Syndrome (PWS) - Dormant Projects, H2 2017 Prader-Willi Syndrome (PWS) - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
